CA3215371A1 - Compositions et methodes de traitement de lesions chroniques actives de la matiere blanche/syndrome radiologiquement isole - Google Patents

Compositions et methodes de traitement de lesions chroniques actives de la matiere blanche/syndrome radiologiquement isole Download PDF

Info

Publication number
CA3215371A1
CA3215371A1 CA3215371A CA3215371A CA3215371A1 CA 3215371 A1 CA3215371 A1 CA 3215371A1 CA 3215371 A CA3215371 A CA 3215371A CA 3215371 A CA3215371 A CA 3215371A CA 3215371 A1 CA3215371 A1 CA 3215371A1
Authority
CA
Canada
Prior art keywords
sel
patient
sels
natalizumab
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215371A
Other languages
English (en)
Inventor
Shibeshih Mitiku BELACHEW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/024450 external-priority patent/WO2022221297A1/fr
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CA3215371A1 publication Critical patent/CA3215371A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

L'invention concerne des méthodes d'administration de thérapies par anticorps modifiant une maladie à des patients atteints de sclérose en plaques asymptomatiques et/ou précoces, y compris des patients atteints du syndrome radiologiquement isolé, sur la base de l'identification et/ou de la co-localisation de lésions à expansion lente et de lésions à rebord paramagnétique dans des images de résonance magnétique provenant desdits patients.
CA3215371A 2021-04-13 2022-04-13 Compositions et methodes de traitement de lesions chroniques actives de la matiere blanche/syndrome radiologiquement isole Pending CA3215371A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163174399P 2021-04-13 2021-04-13
US63/174,399 2021-04-13
FR2103793 2021-04-13
FRFR2103793 2021-04-13
US202263320655P 2022-03-16 2022-03-16
US63/320,655 2022-03-16
PCT/US2022/024450 WO2022221297A1 (fr) 2021-04-13 2022-04-12 Procédés de classification de lésions et de prédiction de développement de lésion
USPCT/US2022/024450 2022-04-12
PCT/US2022/024694 WO2022221458A1 (fr) 2021-04-13 2022-04-13 Compositions et méthodes de traitement de lésions chroniques actives de la matière blanche/syndrome radiologiquement isolé

Publications (1)

Publication Number Publication Date
CA3215371A1 true CA3215371A1 (fr) 2022-10-20

Family

ID=81851070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215371A Pending CA3215371A1 (fr) 2021-04-13 2022-04-13 Compositions et methodes de traitement de lesions chroniques actives de la matiere blanche/syndrome radiologiquement isole

Country Status (5)

Country Link
EP (1) EP4323407A1 (fr)
JP (1) JP2024513974A (fr)
AU (1) AU2022259605A1 (fr)
CA (1) CA3215371A1 (fr)
WO (1) WO2022221458A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
JP2010529999A (ja) 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
DK3575792T3 (da) 2011-05-31 2023-02-27 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
WO2014193804A1 (fr) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp

Also Published As

Publication number Publication date
JP2024513974A (ja) 2024-03-27
AU2022259605A1 (en) 2023-11-02
EP4323407A1 (fr) 2024-02-21
WO2022221458A1 (fr) 2022-10-20

Similar Documents

Publication Publication Date Title
Rahmanzadeh et al. Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging
Amoroso et al. Complex networks reveal early MRI markers of Parkinson’s disease
Tur et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Schmidt-Wilcke et al. Diminished white matter integrity in patients with systemic lupus erythematosus
Zhang et al. Characterization of white matter changes along fibers by automated fiber quantification in the early stages of Alzheimer's disease
Calvi et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis
Pustina et al. Predicting the laterality of temporal lobe epilepsy from PET, MRI, and DTI: a multimodal study
Chiapponi et al. Age-related brain trajectories in schizophrenia: a systematic review of structural MRI studies
Goldsmith et al. Penalized functional regression analysis of white-matter tract profiles in multiple sclerosis
US20210228079A1 (en) Method for early prediction of neurodegenerative decline
Kuchling et al. Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders
Dadar et al. Beware of white matter hyperintensities causing systematic errors in FreeSurfer gray matter segmentations!
Vasta et al. Hippocampal subfield atrophies in converted and not-converted mild cognitive impairments patients by a Markov random fields algorithm
Rabasté et al. Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy
Cervo et al. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis
Rajagopalan et al. Differential involvement of corticospinal tract (CST) fibers in UMN-predominant ALS patients with or without CST hyperintensity: A diffusion tensor tractography study
Stone et al. Specific white matter tracts and diffusion properties predict conversion from mild cognitive impairment to Alzheimer’s disease
Lou et al. Fully automated detection of paramagnetic rims in multiple sclerosis lesions on 3T susceptibility-based MR imaging
Hamzaoui et al. Positron Emission Tomography with [18F]‐DPA‐714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression
Zivadinov et al. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures
Miller et al. Advances in imaging to support the development of novel therapies for multiple sclerosis
Ma et al. Identifying mild cognitive impairment with random forest by integrating multiple MRI morphological metrics
Shu et al. An integrative nomogram for identifying early-stage Parkinson's disease using non-motor symptoms and white matter-based radiomics biomarkers from whole-brain MRI
Liu et al. Multi-parametric diffusion tensor imaging of the optic nerve for detection of dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy
Münch et al. Segmental alterations of the corpus callosum in motor neuron disease: A DTI and texture analysis in 575 patients